HEK-Blue™ IL-36 Cells
-
Cat.code:
hkb-hil36r
- Documents
ABOUT
IL-36 responsive NF-κB/AP1-SEAP reporter assay
HEK-Blue™ IL-36 cells are designed to monitor human IL-36-induced NF-κB/AP1 stimulation or inhibition. This colorimetric cytokine bioassay can be used to screen activatory or inhibitory molecules, such as engineered cytokines and neutralizing antibodies.
HEK-Blue™ IL-36 cells respond to recombinant human IL-36α, IL-36β, and IL-36γ, but not to mouse IL-36 (see figures). Their reliable and consistent performance makes them suitable for release assays of activatory and inhibitory molecules such as Imsidolimab, a monoclonal antibody that targets the IL-36 receptor (IL-36R) and prevents IL-36 signaling (see figures).
Key features
- Readily assessable NF-κB/AP-1-inducible SEAP reporter activity
- Convenient readout using QUANTI-Blue™ Solution
- Strong response to human (h) IL-36α and IL-36γ
- No response to mouse (m) IL-36α
- Stability guaranteed for 20 passages
Applications
- Therapeutic development
- Drug screening
- Release assay
The interleukin-36 (IL-36) belongs to the IL-1 superfamily and comprises multiple isoforms, whereas IL-36α, IL-36β, and IL-36γ mediate pro-inflammatory functions, while a fourth one, IL-36Ra, acts as an antagonist. Dysregulation of IL-36 isoform expression and signaling has been associated with inflammatory diseases such as psoriasis, rheumatoid arthritis, and inflammatory bowel disease.
Disclaimer: These cells are for internal research use only and are covered by a Limited Use License (See Terms and Conditions). Additional rights may be available.
SPECIFICATIONS
Specifications
IL-36
Human
Detection and quantification of IL-36 activity
30 pg/ml - 100 ng/ml (hIL-36α, hIL-36γ)
10 ng/ml - 100 ng/ml (hIL-36β)
Complete DMEM (see TDS)
Verified using Plasmotest™
Each lot is functionally tested and validated.
CONTENTS
Contents
-
Product:HEK-Blue™ IL-36 Cells
-
Cat code:hkb-hil36r
-
Quantity:3-7 x 10^6 cells
- 1 ml Normocin® (50 mg/ml)
- 1 ml Blasticidin™ (10 mg/ml)
- 1 ml Zeocin® (100 mg/ml)
- 1 ml of QB reagent and 1 ml of QB buffer (sufficient to prepare 100 ml of QUANTI-Blue™ Solution, a SEAP detection reagent)
Shipping & Storage
- Shipping method: Dry ice
- Liquid nitrogen vapor
- Upon receipt, store immediately in liquid nitrogen vapor. Do not store cell vials at -80°C.
Storage:
Caution:
Details
Cell line description
HEK-Blue™ IL-36 cells were generated by stable transfection with the genes encoding for the human IL-36 heterodimeric receptor, comprising the IL-1R6 (aka IL-36R) and IL-1R3 (aka IL-1RAcP) subunits, and an NF-κB/AP-1-inducible secreted embryonic alkaline phosphatase (SEAP) reporter. The binding of IL-36 to its receptor triggers a signaling cascade leading to the NF-κB/AP-1 activation and the subsequent production of SEAP.
HEK-Blue™ IL-36 cells respond to human (h) but not murine (m) IL-36 agonist isoforms. Of note, they are more sensitive to hIL-36α and hIL-36γ compared to hIL-36β (see figures). HEK-Blue™ IL-36 cells maintain their responses to other cytokines that signal through NF-κB/AP-1, such as hIL-1β and hTNF-α (see figures).
IL-36 background
The cytokine interleukin 36 (IL-36) belongs to the IL-1 superfamily. Three isoforms, IL-36α, IL-36β, and IL-36γ, mediate pro-inflammatory functions, while a fourth one, IL-36Ra, acts as an antagonist [1,2]. IL-36 signalization requires the formation of a complex comprised of two subunits, IL-1R6 (aka IL-36R) and IL-1R3 (aka IL-1RAcP, IL-1 receptor accessory protein). The binding of agonist ligands to the IL-36R allows the recruitment of IL-1RAcP and the production of pro-inflammatory cytokines and chemokines through the activation of NF-κB and AP-1 [1,2]. The IL-36Ra antagonist inhibits the signaling by binding to IL-36R and preventing the recruitment of IL-1RAcP [1,2]. IL-36-associated immune response mainly takes place in barrier tissues, such as the skin, lungs, and intestines. Dysregulation of IL-36 isoform expression and signaling has been associated with inflammatory diseases such as psoriasis, rheumatoid arthritis, and inflammatory bowel disease [1,2].
References:
1. Buhl A-L. & Wenzel J., 2019. Interleukin-36 in infectious and inflammatory skin diseases. Front. Immunol. 10(1162). doi: 10.3389/fimmu.2019.01162.
2. Zhou L. & Todorovic V., 2021. Interleukin-36: Structure, Signaling and Function. Protein Reviews: Volume 21. doi: 10.1007/5584_2020_488.
DOCUMENTS
Documents
Technical Data Sheet
Validation Data Sheet
Safety Data Sheet
Certificate of analysis
Need a CoA ?